Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BlossomHill TherapeuticsBLSM -0.06%8 Current Ratio is 8.97 as of Dec. 2025. GuruFocus rates BLSM with a GF Score™ of 8/100. Among 1,405 Biotechnology companies, BlossomHill Therapeutics ranks worse than 71174.31% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BlossomHill Therapeutics's current ratio for the quarter that ended in Dec. 2025 was 8.97.
BlossomHill Therapeutics has a current ratio of 8.97. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for BlossomHill Therapeutics's Current Ratio or its related term are showing as below:
BLSM's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.83 * Ranked among companies with meaningful Current Ratio only.
BlossomHill Therapeutics (NAS:BLSM) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BlossomHill Therapeutics Current Ratio Related Terms
BlossomHill Therapeutics Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BlossomHill Therapeutics Current Ratio Chart
BlossomHill Therapeutics Annual Data
Trend
Dec24
Dec25
Current Ratio
15.38
8.97
BlossomHill Therapeutics Semi-Annual Data
Dec24
Dec25
Current Ratio
15.38
8.97
BLSM vs : Current Ratio Comparison
For the Biotechnology subindustry, BlossomHill Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BlossomHill Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BlossomHill Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where BlossomHill Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BlossomHill Therapeutics (BLSM) has a Current Ratio of 8.97 as of Dec. 2025. According to the industry distribution chart, BlossomHill Therapeutics ranks #999999 out of 1405 companies in the Biotechnology industry.
Is BlossomHill Therapeutics' Current Ratio too high?
BlossomHill Therapeutics' current Current Ratio is 8.97. The Biotechnology industry median Current Ratio is 3.83. BlossomHill Therapeutics' value of 8.97 is 134.2% above this industry median. Based on the distribution chart, BlossomHill Therapeutics ranks #999999 out of 1405 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Current Ratio compare to ?
According to the Biotechnology industry distribution chart, BlossomHill Therapeutics ranks #999999 out of 1405 companies for Current Ratio. This places BlossomHill Therapeutics in the lower half of its industry. The industry median Current Ratio is 3.83. BlossomHill Therapeutics' value of 8.97 is 134.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.83, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BlossomHill Therapeutics's current Current Ratio of 8.97 is 134.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BlossomHill Therapeutics's current Current Ratio is 8.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Current Ratio of 8.97. The current Current Ratio is 8.97 and 134.2% above the Biotechnology industry median of 3.83. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Current Ratio is 8.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score
Get the complete analysis for BLSM
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLSM has been successfully added to your 
